Company / Capital Expenditures
MADRIGAL PHARMACEUTICALS, INC. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$467.0K
FY2025
5-year range
$209.0K / $1.5M
FY2021-FY2025
Trend
-68.1%
vs FY2024
Sector context
#140 of 194
Health Care
What the data says
At $467,000, MADRIGAL PHARMACEUTICALS, INC.'s capital expenditures ranks #140 of 194 in the Health Care sector. Capital Expenditures has fluctuated over the past 10 years, ranging from $3,000 in FY2016 to $1M in FY2023.
Based on SEC 10-K filings.
$467,000 in FY2025 with a 5-year CAGR of +6.9%.
Declined from $1M to $467,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +29.1%
- 5-Year CAGR
- +6.9%
- 10-Year CAGR
- -
Sector benchmark
#140 of 194 in Health CareTop 72% of 194This company $467.0K Sector average $117.5M
▼
-99.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +6.9%, indicating consistent growth.
- In FY2025, capital expenditures decreased 68.1% year-over-year.
- Ranks #140 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $467.0K | -68.1% |
| FY2024 | $1.5M | -1.1% |
| FY2023 | $1.5M | +581.6% |
| FY2022 | $217.0K | +3.8% |
| FY2021 | $209.0K | -37.4% |
| FY2020 | $334.0K | +94.2% |
| FY2019 | $172.0K | +681.8% |
| FY2018 | $22.0K | -82.4% |
| FY2017 | $125.0K | +4066.7% |
| FY2016 | $3.0K | -97.9% |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026